Played around with ChatGPT about a buyout from Merck being that it would help Keytruda. It estimated Keytruda revenue could increase by $10-$20 billion a year if LL increases PD-L1 on all solid tumors. The starting point that Cytodyn should even entertain would be 1x the additional revenue the Merck expects to earn from Keytruda. Keytruda has like a 75% profit margin so they would make their money back from the purchase of Cytodyn in less than two years. That number doesn't even reflect the revenue they would receive for selling LL nor does it consider all of the other potential indications that LL can treat so the minimum I would be okay with is $20 billion which is currently around $13.33/share.